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Abstract
Changes in whole body energy levels are closely linked to alterations in body weight and bone mass. Here, we show that
hypothalamic signals contribute to the regulation of bone mass in a manner consistent with the central perception of
energy status. Mice lacking neuropeptide Y (NPY), a well-known orexigenic factor whose hypothalamic expression is
increased in fasting, have significantly increased bone mass in association with enhanced osteoblast activity and elevated
expression of bone osteogenic transcription factors, Runx2 and Osterix. In contrast, wild type and NPY knockout (NPY 2/2)
mice in which NPY is specifically over expressed in the hypothalamus (AAV-NPY+) show a significant reduction in bone mass
despite developing an obese phenotype. The AAV-NPY+ induced loss of bone mass is consistent with models known to
mimic the central effects of fasting, which also show increased hypothalamic NPY levels. Thus these data indicate that, in
addition to well characterized responses to body mass, skeletal tissue also responds to the perception of nutritional status
by the hypothalamus independently of body weight. In addition, the reduction in bone mass by AAV NPY+ administration
does not completely correct the high bone mass phenotype of NPY 2/2 mice, indicating the possibility that peripheral NPY
may also be an important regulator of bone mass. Indeed, we demonstrate the expression of NPY specifically in osteoblasts.
In conclusion, these data identifies NPY as a critical integrator of bone homeostatic signals; increasing bone mass during
times of obesity when hypothalamic NPY expression levels are low and reducing bone formation to conserve energy under
‘starving’ conditions, when hypothalamic NPY expression levels are high.
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Introduction
Bone remodelling has traditionally been viewed as an
endocrine- and paracrine-regulated process. This view is rapidly
changing, however, with growing evidence demonstrating that
neuronal factors are critical for normal bone homeostasis.
Moreover, efferent neural pathways from the hypothalamus
potently modify the activity of bone cells. Studies in leptin-
deficient (ob/ob) mice revealed that the adipokine leptin, in
addition to its actions as an important circulating indicator of the
level of adiposity, also modulates bone formation through
activation of central, hypothalamic relays via efferent sympathetic
nervous output which directly modulates osteoblast activity [1–3].
A major target of leptin in the hypothalamus is the neuropeptide Y
(NPY) system, one of the most prominent regulators of appetite
and energy homeostasis [4]. Leptin down-regulates NPY expres-
sion in the hypothalamus and in this way reduces appetite and
normalises energy expenditure [5]. Importantly however, the NPY
system has also been shown to regulate bone homeostasis [6].
Amongst the 5 known Y-receptors (Y1, Y2, Y4, Y5 and in certain
species also Y6) [7,8], NPY mediates its effects on energy
homeostasis via hypothalamic Y1 and Y2 receptors [6]. Interest-
ingly, these Y-receptors have also been reported to be critical in
the regulation of bone homeostasis with the specific deletion of the
Y2-receptor in the hypothalamus resulting in a bone anabolic
phenotype [6].
However, the actions of the NPY system in bone are more
complex than a simple downstreammediator for leptin. Specifically,
Y2-mediated changes occur consistently throughout the skeleton in
these mice, while alterations in leptin levels induce opposing effects
on cortical and cancellous bone, as evident in studies involving
Y22/2;ob/ob double mutant mice [9]. Furthermore, Y1 receptors
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have been identified on osteoblasts and a lack of Y1 receptors in
mice also leads to increased bone mass [10]. The Y1-mediated effect
on bone is not dependent on hypothalamic Y1 receptors suggesting
an additional direct action of the NPY system on bone homeostasis
[6,8,11].
Despite the demonstrated actions of NPY, Y receptors in the
control of bone homeostasis, the role of NPY in this process is yet to
be defined. Although NPY is the predominant ligand in the central
nervous system, Y receptors can also be activated by the two other
family members, peptide YY (PYY) and pancreatic polypeptide
(PP). Possible redundancy in the functions of NPY-like ligands may
explain why initial examination of NPY deficient mice suggested no
skeletal changes [12], a finding contradictory to experiments
showing significant increases in bone mass following loss of NPY-
producing neurons from the arcuate nucleus of the hypothalamus
using monosodium glutamate treatment by the same group [13].
Therefore we used a systematic approach to investigate the specific
role of NPY signalling on bone homeostasis employing several NPY
mutant mouse models including specific re-introduction of NPY
into the hypothalamus of otherwise NPY deficient adult mice.
Results
High Bone Mass and Reduced Fat Mass in NPY 2/2 Mice
While there was no effect of NPY ablation on body weight
(Figure 1a), body fat mass was significantly reduced in NPY 2/2
compared to wild type mice, as evidenced by decreased whole
body fat mass measured by DXA (Figure 1b), with no effect of
genotype on lean body mass (Figure 1c). Importantly, lack of NPY
was associated with a greater whole body BMD as well as a greater
whole body BMC apparent in both genders, although the increase
in BMC only reached significance in female NPY 2/2 (Figure 1d,
1e). Consistent with the whole body measurement, lumbar BMD
and BMC were significantly increased in NPY 2/2 mice compared
to gender-matched wild type controls (Figure 1f, 1g).
Greater Cortical Bone Formation in NPY 2/2 Mice
In order to evaluate the DXA results, cortical bone was
examined by peripheral quantitative tomography. There was a
significant increase in cortical bone size in NPY 2/2 mice. Total
bone volume and marrow volume of the mid-femur of NPY 2/2
mice were both increased, resulting in greater cortical bone
volume and cortical thickness in NPY 2/2 mice compared to wild
type (Figure 2a–2d). These changes were associated with enhanced
cortical bone formation, as shown by elevated endocortical
mineral apposition rate (MAR) (Figure 2e, 2f). Importantly, these
changes in cortical bone mass and formation were evident in the
absence of any increases in motor activity in either male or female
NPY 2/2 mice, negating a potential role of activity and weight
bearing in the increases in bone mass seen in these mice
(Figure 2g). Indeed, a trend for reduced physical activity was
evident in NPY 2/2 mice in the dark phase, but this was not
significant, nor was it seen in the overall 24-hour period
(Figure 2g).
Generalized Increase in Bone Formation in NPY 2/2 Mice
In the distal femoral metaphysis, cancellous bone volume was
greater in NPY 2/2 mice, coincident with a 2-fold increase in bone
formation rate compared to that in wild type mice (Figure 3a, 3b).
This change was associated with an increase in the extent
(mineralizing surface) and speed (mineral apposition rate) of bone
formation (Figure 3c, 3d). Bone resorption indices in NPY 2/2
mice – i.e. osteoclast surface and number – were not significantly
changed (Figure 3e, 3f), demonstrating that NPY preferentially
controls the anabolic aspects of bone homeostasis. Femoral data is
shown for male mice, but results were similar in females. The
effects of NPY deletion on femoral cancellous bone were also
evident in micro computed tomographs of the distal femoral
metaphysis (Figure 1g) and cancellous bone volume of the 4th
lumbar vertebrae (Figure 1h), indicating a generalized anabolic
effect of NPY deletion throughout the skeleton.
Elevated Hypothalamic NPY Expression Reduces Bone
Formation
To investigate whether alterations in central NPY levels are
responsible for the anabolic bone phenotype seen in NPY 2/2
mice, NPY was over-expressed specifically in the hypothalamus of
Figure 1. Generalized bone anabolic phenotype in 4 month old male and female NPY 2/2 mice. (a) Body weight. Dual X-ray
absorptiometry analysis of (b) fat mass, (c) lean mass indicate changed energy homeostasis in NPY 2/2 mice. Bone mass and density was also greater
as seen in (d) whole body BMD, (e) whole body BMC, (f) lumbar BMD and (g) lumbar BMC. n = 8214, data expressed as mean6SE.
doi:10.1371/journal.pone.0008415.g001
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adult wild type mice. Wild type mice were injected unilaterally
with a recombinant adenovirus-associated virus producing a
localized increase in NPY expression (rAAV-NPY+) in the
hypothalamus, targeting the arcuate nucleus (Arc) (Figure 4a),
the brain region critical in mediating the central effects of Y
receptor signaling on both energy balance and bone mass [6,8].
Four weeks post-injection, body weight was significantly increased
in wild type rAAV-NPY+-injected animals (WT NPY+) compared
to wild type controls, injected with an empty virus (WT empty)
(Figure 4b). This weight gain was associated with an increase in
white adipose tissue mass (Figure 4c).
Given the strong and positive association between increases in
body weight and bone mass, in part due to mechanical effects of
weight bearing [14], it is notable that tibial BMC was reduced by
19% (p,0.05) in WT NPY+ mice compared to WT empty
controls over the 4-week period, with no change in tibial BMD
(Figure 4d, 4e). This NPY-mediated bone loss was due to the
specific action of NPY in the hypothalamus, as no changes in bone
homeostasis were evident following rAAV-NPY+ injection into the
hippocampus [8]. Histological examination of bones revealed that
elevation of hypothalamic NPY expression decreased cortical
osteoblast activity, with a 7-fold reduction in endosteal MAR and a
significant reduction in periosteal MAR in WT NPY+ mice
compared to WT empty controls (Figure 4f, g). These changes can
be clearly seen on the endosteal surface after injection of dual
fluorescent labels (Figure 4h), demonstrating the powerful action of
hypothalamic-NPY activated pathways on inhibiting osteoblast
activity.
In order to determine whether the bone anabolic phenotype
observed in NPY 2/2 mice is wholly due to the lack of
hypothalamic NPY signaling, an additional transgenic mouse
model was generated where NPY expression was restricted solely
to the hypothalamus. This model was achieved by re-introducing
NPY specifically into the hypothalamus of NPY 2/2 mice via
stereotactic injection of rAAV-NPY+ (NPY 2/2 NPY+). As shown
in Figures 4i and 4j, NPY 2/2 NPY+ -mice had a greater body
Figure 2. Greater cortical bone in NPY 2/2 mice. Peripheral quantitative computed tomography of mid-femur in male mice showing (a) total
bone volume, (b) marrow volume, (c) cortical bone volume and (d) cortical thickness. (e) Mid femoral endocortical mineral apposition rate, (f)
photomicrograph of endocortical bone formation. (g) 24 hour home cage activity. Scale bar represents 50 mm.# p,0.05 vs wild type. n = 8214, data
expressed as mean6SE.
doi:10.1371/journal.pone.0008415.g002
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weight gain and more than doubled adiposity within 4 weeks
compared to NPY 2/2 empty mice, confirming the viability of the
NPY reintroduction procedure and demonstrating the critical role
hypothalamic NPY plays in regulating body weight and fat mass.
Interestingly however, the elevated bone mass and bone formation
seen in NPY 2/2mice was only partially corrected by hypothalamic
re-introduction of NPY in otherwise NPY deficient mice. As shown
above, global deletion of NPY led to a 40% increase in MAR in
femoral cancellous bone compared to wild type controls (Figure 3d).
However, restoration of NPY expression in the hypothalamus of
NPY 2/2mice resulted only in a partial normalization of MAR to a
level approximately 20% lower then NPY 2/2 mice, with similar
reductions in the change in femoral bone mass and cancellous bone
volume (Figure 4k–4m). This inability of hypothalamic NPY to
completely restore a normal bone phenotype in NPY 2/2 mice
suggests that non-hypothalamic pathway(s) may also be important
in NPY mediated bone homeostasis.
NPY Signalling on Bone Cells Alters Osteogenesis In Vivo
and In Vitro
In order to clarify whether NPY also regulates bone homeostasis
by direct action on bone cells and whether NPY is expressed in
bone tissue itself, bone sections were examined by in situ
hybridisation. Both cancellous and cortical osteoblasts from wild
type mice stained positively for NPY mRNA (Figure 5a) with no
staining in NPY 2/2 bone tissue (Figure 5b), providing the first
evidence of NPY expression in osteoblasts in vivo.
To further investigate what role NPY may play in osteoblast
function and development, mRNA was isolated from the bones of
wild type and NPY 2/2 mice and analysed for the expression of
key osteogenic markers. In keeping with their high bone mass and
anabolic phenotype, mRNA expression of alkaline phosphatase
(ALP) was significantly up-regulated in the long bones of NPY 2/2
mice (Figure 5c). Importantly, there was also an up-regulation of
both Runx2, and Osterix mRNA levels in the NPY 2/2 mice
(Figure 5c). Moreover, in vitro osteoblast activity was enhanced in
the absence of NPY, evident by a greater time-dependent increase
in mineralisation by NPY 2/2 bone marrow stromal cells under
osteogenic conditions than cells isolated from wild type mice
(Figure 5d).
Taken together, these data indicate that global lack of NPY
induces effects inherent to osteoblasts in both cortical and
cancellous bone and in the apical and appendicular skeletons.
Given that NPY is expressed in osteoblasts, these data further
support the concept that NPY could be a direct local regulator of
osteoblast function, in addition to effects mediated via the
hypothalamus, and highlights the fact that NPY may act via
neuronal as well as autocrine mechanisms to regulate bone
homeostasis.
Discussion
This study has identified a powerful inverse relationship
between NPY signaling in the hypothalamus and bone formation.
A generalized bone anabolic response resulting from loss of NPY
Figure 3. Greater cancellous bone volume and formation in NPY 2/2mice. Histomorphometric analysis of distal femoral metaphysis in male
mice showing (a) cancellous bone volume, (b) bone formation rate, (c) mineralizing surface, (d) mineral apposition rate, (e) osteoclast surface and (f)
osteoclast number. (g) Representative micro-computed tomographs of the distal femoral metaphysis of 4 month old male wild type and NPY 2/2
mice. (h) 4th lumbar vertebral sections from male wild type and NPY 2/2 mice, displaying greater cancellous bone volume (BV/TV) in mutant mice. #
p,0.05 vs wild type. n = 8214, data expressed as mean6SE.
doi:10.1371/journal.pone.0008415.g003
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signaling was evident throughout the skeleton, including cortical
and cancellous bone as well as axial and appendicular sites. In
contrast, NPY over expression in the hypothalamus resulted in an
inhibition of bone formation. This central action is consistent with
signaling via Y2 receptors expressed on neurons of the arcuate
nucleus, as is evidenced by the opposing response reported
following specific deletion of Y2 receptors from this region of the
hypothalamus [6]. Thus NPY acts in the hypothalamus to
tonically inhibit bone formation, and likely does so through
signals transduced by Y2 receptors.
Results from this study suggest that in addition to the well defined
actions of loading from body weight on bone mass, the central
‘perception’ of energy status may have an important influence on
bone mass. This is particularly evident in rAAV-NPY+ injected
mice. The viral promoter controlling NPY production prevents the
normal feedback by signals such as increased serum leptin from
inhibiting hypothalamic NPY expression [12,15]. As a result, the
‘‘starvation’’ signal is not attenuated and body weight continues to
increase. Importantly, despite the marked increase in body weight
caused by this experimental condition, a decrease in bone mass
occurred. While the decrease in bone formation in these mice may
in part also result from reduced physical activity [16] and thereby
altered weight bearing [17], this result is also consistent with a
skeletal response to the starvation signal induced by AAV NPY+
[18]. Thus the central perception of body weight may be important
to the regulation of bone mass, in addition to the actual mechanical
forces in the bone tissue itself. In this manner, during weight loss,
increasing NPY ensures calories are not wasted on the production/
maintenance of unneeded skeletal tissue, thereby also increasing the
supply of minerals and nutrients stored in skeletal tissue for other
vital processes. Conversely, during periods of high nutrient intake
and resultant weight gain, reduction in NPY expression ensures
sufficient bone formation to guarantee mechanical competence of
the skeleton during the period of increased weight bearing.
Importantly, we showed here that reduced NPY levels in NPY
knockout mice are not associated with significant changes in activity
levels, indicating the skeletal response to NPY are not activity-
dependent. NPY is therefore ideally placed to match bone mass to
body weight, a major regulatory influence on bone homeostasis [19]
(Figure 6b).
Figure 4. Hypothalamic NPY over-expression inhibits bone formation, despite increased body weight. Photomicrograph of coronal
brain section showing NPY over expression following unilateral rAAV-NPY+ injection in the arcuate nucleus (Arc). Changes in (b) body weight, (c)
white adipose tissue, (d) tibial BMD, (e) tibial BMC, (f) mid femoral endocortical and (g) mid femoral periosteal mineral apposition rate in response to
hypothalamic NPY over expression in wild type mice (WT NPY+) compared to control (WT empty). (h) Representative photomicrographs of femoral
endocortical mineral apposition rate WT empty or WT NPY+ mice. Changes in (i) body weight, (j) fat mass, (k) distal femoral metaphyseal mineral
apposition rate, (l) femoral BMD, and (m) distal femoral metaphyseal cancellous bone volume in germline NPY 2/2 mice after hypothalamic NPY over
expression (NPY 2/2 NPY+) compared to controls (NPY 2/2 empty). # p,0.05 vs empty. Scale bar represents 20 mm. n=7212, data expressed as
mean6SE.
doi:10.1371/journal.pone.0008415.g004
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Central circuits alone, however, do not appear to explain the
entire NPY-mediated signaling pathway to bone, as restoration of
hypothalamic NPY expression in NPY 2/2 mice failed to
completely normalize osteoblast activity. This incomplete rescue
of the NPY 2/2 phenotype by central NPY replacement indicates a
potential role for non-hypothalamic NPY pathways. This finding is
consistent with a Y1 receptor-mediated action in the periphery,
since hypothalamus-specific deletion of Y1 receptors did not
replicate the greater bone formation evident in germline Y12/2
mice [10]. This opens the possibility that lack of NPY in
osteoblasts may have contributed to the phenoptype of NPY 2/2
mice, consistent with our demonstration of NPY expression in
osteoblasts, altered expression of osteogenic transcription factors in
bone as well as increased ex vivo mineralization of osteoblasts from
NPY 2/2 mice. Indeed, identification of NPY expression in the
osteoblast, along with local expression of Y1 receptor [10,20]
indicates the potential for local paracrine/autocrine control of
osteoblast activity by NPY. Interestingly, in terms of NPY’s
coordination of body weigh and bone mass, NPY expression has
been identified in both osteoblasts and osteocytes [10,20].
Moreover, this expression was reduced following exposure of
cultured osteoblasts to fluid sheer stress, indicating the potential for
a local, load-responsive regulation of NPY. In this manner,
increasing load would decrease NPY expression, thereby reducing
the tonic repression of osteoblast activity as body weight increased.
Thus central efferent signals may provide a systemic regulatory
influence, via Y2 receptor action in the arcuate nucleus of the
hypothalamus, whilst osteoblastic Y1 receptor action may enable
local fine-tuning of the systemic response (Figure 6a).
Taken together, these data highlight the critical role of NPY in
the co-ordinated regulation of skeletal tissue. We propose that in
situations where hypothalamic NPY expression is decreased, as in
short-term overfeeding in which serum leptin levels rise and in turn
reduces central NPY signaling [12,15], bone formation is stimulated
as was the case in NPY 2/2 mice. Moreover, when central NPY
levels are elevated as in negative energy balance, bone formation is
inhibited as was the case in rAAV-NPY+ injected mice. While
hypothalamic NPY is ideally placed to modify bone mass to match
changes in body weight induced by altered energy homeostasis,
NPY produced in bone itself may play an important role in the
regulation of bone mass. This later circuit offers also an attractive
target to modulate and opens the possibility to increase bone mass
without affecting central NPY controlled pathways.
Materials and Methods
Generation of NPY 2/2 Mice
The generation of the NPY 2/2 mice was described previously
[21]. All research and animal care procedures were approved by
the Garvan Institute/St Vincent’s Hospital Animal Experimenta-
tion Ethics Committee and were in agreement with the Australian
Code of Practice for the Care and Use of Animals for Scientific
Purpose.
Viral Vector Injection
Elevation of NPY expression was achieved following procedures
reported previously [8]. Briefly, 10–12 week-old wild type or NPY 2/2
mice were anesthetized and injected in the PVN with recombinant
adeno-associated virus expressing either NPY (rAAV-NPY+) or an
empty cassette (rAAV-empty) using a stereotaxic table (David Kopf,
California, USA). Brain injection co-ordinates relative to Bregma
were posterior, 2.1 mm; lateral, 60.4 mm; ventral, 5.3 mm
corresponding to the PVN [22]. An additional control group was
injected with rAAV-NPY+ or rAAV-empty vector in the hippocam-
pus (Co-ordinates relative to Bregma were posterior, 1.7 mm; lateral,
60.8 mm; ventral, 2.2 mm). One microlitre of either rAAV-NPY+
Figure 5. NPY expression and action in bone tissue. (a) Analysis of NPY expression by in situ hybridisation in wild type mice shows specific
staining of osteoblasts employing a NPY antisense probe in cancellous and cortical bone (arrows) and megakaryocytes (arrowheads). (b) This staining
is absent in NPY 2/2mice. (c) Levels of ALP, Runx2 and Osterix are greater in NPY 2/2mice compared to wild type as determined by quantitative real-
time PCR on mRNA from long bones. (mean6SE. n = 526 mice per genotype.). (d) Bone marrow stromal cells isolated from NPY 2/2 mice produce
more mineral in vitro than wild type mice. (mean6SE, n = 10215 wells per time, 3 independent experiments). # p,0.05, ## p,0.01 vs wild type,
scale bar represents 50 mm.
doi:10.1371/journal.pone.0008415.g005
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or rAAV-empty virus (16109 Pfu/ml) was injected bilaterally over 10
minutes using a 26 gauge guide cannula and a 33 gauge injector
(PlasticsOne, Roanoke, USA) connected to a Hamilton Syringe and a
syringe infusion pump (World Precision Instruments, Sarasota,
Florida). The recombinant AAV expressing NPY was under the
control of a neuron specific enolase promoter (rAAV-NPY+), which
confined the expression to nerve cells. Mice were housed individually
for the ensuing 28 days, with ad libitum access to standard chow and
water. The efficacy of viral NPY expression was confirmed by the
resultant weight gain, a characteristic response to elevated hypotha-
lamic NPY production [8].
Activity Measurements
Ambulatory activity of individually housed mice was evaluated
within the metabolic chambers using an OPTO-M3 sensor system
(Columbus Instruments, Columbus, OH, USA), whereby ambu-
latory counts were a record of consecutive adjacent photo-beam
breaks. Cumulative ambulatory counts of X, Y and Z directions
were recorded every minute and summed for 1-h intervals.
Bone Histomorphometry
Mice were injected with the fluorescent compound calcein
(Sigma Chemical Company, St Louis, USA) at 20 mg/kg (s.c.) at
10 and 3 days prior to collection. At 14–16 weeks of age, WT and
NPY 2/2 mice were sacrificed by cervical dislocation between
10.00–14.00 h for collection of trunk blood in heparinized tubes.
Both femora and the lumbar spine were excised and fixed in 4%
paraformadehyde for 16 h at 4uC. The right femur was bisected
transversely at the midpoint of the long axis and the distal half
embedded undecalcified in methacrylate resin (Medim-Medizi-
nische Diagnostik, Giessen, Germany). Similarly, the 4th lumbar
vertebrae was defleshed and embedded. Sagittal sections with
5 mm thickness were analysed as previously described [11].
Mineralized bone in the sections was visualized by von Kossa
stain. Cancellous bone volume, trabecular thickness and number
were calculated. The mineralizing surface (MS, %), mineral
apposition rate (MAR, mm/d) and bone formation rate
(BFR=MS/BS * MAR, mm2/ mm/d) were calculated as
previously described [8], following fluorescence microscopy (Leica,
Heerbrugg, Switzerland). Osteoclast surface and osteoclast
number were estimated in tartrate-resistant acid phosphatase
stained sections where only multinucleated, TRAP-positive cells
were included in the analysis. Cortical mineral apposition rate was
measured on the anterior periosteal surface in a region extending
1000 mm distal from the mid point of the shaft and in an endosteal
region extending 1000 mm proximal from the posterior aspect of
the growth plate as previously described [8].
Figure 6. Schematic representation of the co-ordinate regulation of body weight and bone by NPY. (a) Altered energy homeostatic
demand regulates hypothalamic NPY production, which signals via arcuate Y2 receptors through efferent sympathetic relays to the osteoblast. At the
osteoblast, tonic cell activity is modulated by exogenous neural inputs as well as local NPY production, acting through cell surface Y1 receptors. (b)
NPY exhibits an inverse relationship with both energy homeostasis and bone mass. As body weight increases as a result of positive energy
homeostasis, the decrease in NPY signaling stimulates the production of bone to match body weight to bone mass. Likewise, negative energy
homeostasis, and the coincident reduction of body weight is accompanied by increased NPY, which inhibits the production of bone, thereby
conserving energy and increasing the mobilization of nutrient stores form bone.
doi:10.1371/journal.pone.0008415.g006
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Bone Densitometry
Whole body bone mineral content (BMC), bone mineral density
(BMD), lean mass and fat mass were measured on mice ventral
side down with head exclusion and tail inclusion, using a dedicated
mouse dual X-ray absorpiometer (DXA) (Lunar Piximus II, GE
Medical Systems, Madison WI). Whole femoral BMC and BMD
were measured in excised left femora. Femora were scanned with
tibiae attached and the knee joint in flexion to ninety degrees to
ensure consistent placement and scan of the sagittal profile.
Micro Computed Tomography
Cancellous bone architecture was evaluated at the distal femoral
metaphysis [23,24]using micro-computed tomography (Micro-
CT40, Scanco Medical AG, Basserdorf Switzerland), employing a
12-mm isotropic voxel size. Bone volume fraction (BV/TV, %) was
computed without assumptions regarding the underlying bone
architecture [25].
Quantitative Computed Tomography (QCT)
QCT was used to isolate cortical bone for analysis in male mice,
using a Stratec XCT Research SA (Stratec Medizintechnik,
Pforzheim, Germany). Scans were conducted on excised left
femurs as previously described [9] with following settings: voxel
size of 70 mm, scan speed of 5 mm/sec and slice width of 0.2 mm.
Bones were scanned in 2 consecutive slices, 7 and 7.5 mm from
the distal margin of the femur, representing a mid femoral aspect.
In-Situ Hybridisation of Bone and Hypothalamic Tissue
Antisense and sense riboprobes for mouse NPY were generated
from a cDNA region corresponding to bases 272 to +89 of the
coding sequence and subcloned into pGEM-T Easy plasmid
vector (Promega). Probes were labelled with digoxigenin-UTP by
in vitro transcription with either SP6 (antisense probe) or T7 (sense
probe) RNA polymerase using a DIG RNA labelling kit (Roche)
according to the manufacturer’s instructions and .purified using
Sephadex G25 spin columns and their yield was assessed by dot
blot.
In situ hybridisation was carried out as previously described with
minor modifications [26] on 5 mm sections of decalcified sagittal
section of the distal femur. All procedures were carried out at
room temperature unless specified otherwise. Sections were
dewaxed in xylene, rehydrated through decreasing concentrations
of ethanol (100% to 70%), and then fixed in 2% paraformalde-
hyde in PBS on ice for 10 minutes. After washing in PBS, sections
were incubated at 37uC with proteinase K (Roche) at a
concentration of 5 mg/mL in 50 mM Tris-HCl (pH 7.5) and
5 mM EDTA for 20 minutes, followed by 0.1 M glycine in PBS
for 5 minutes. Sections were acetylated with 1X triethanolamine
containing 0.25% (v/v) acetic anhydride for 10 minutes and
washed in PBS before hybridisation.
Hybridisation was carried out overnight at 45uC in a humid
environment. Sections were incubated with hybridisation solution
containing 50% formamide, 5X SSC, 250 mg/ml salmon sperm
DNA, 250 mg/ml yeast tRNA, 1x Denhardt’s solution, 10%
dextran sulphate, 10 mM DTT and 200 ng/mL of digoxigenin-
labelled riboprobe. The sections were washed in 2X SSC for 5
minutes followed by 0.2X SSC at 62uC for 30 minutes and 0.1X
SSC at 65uC for 30 minutes. They were then incubated with
20 mg/mL RNase A (Roche) in 0.5 M NaCl, 10 mM Tris-HCl,
and 1 mM EDTA at 37uC for 15 minutes followed by washes with
2X SSC for 5 minutes, 0.1X SSC at 37uC for 30 minutes.
Following the washes, antidigoxigenin Fab antibody fragments
conjugated with alkaline phosphatase (Roche) and NBT/BCIP
stock solution (Roche) containing 1 mM levamisole were used for
colorimetric detection following the manufacturer’s instructions.
Isolation and Differentiation of Bone Marrow Stromal
Cells
The isolation and differentiation of plastic adherent bone marrow
stromal cells (BMSCs) from 5 to 9 week old male mice was carried
out as previously described [10] with minor modifications.
Following sacrifice by cervical dislocation, marrow was flushed
from femurs and tibias with control media and cells were plated at a
density of 1.96106 cells/cm2 in 50 cm2 plastic tissue culture plates.
Control media consisted of a-minimum essential medium contain-
ing 10% fetal bovine serum, 2 mM L-glutamine, 2.2 g/L sodium
bicarbonate, 0.017 MHEPES, 100 mg/mL penicillin/streptomycin
and 34 mg/L gentamycin. The majority of non-adherent cells were
removed by medium changes at 3 and 5 days later and discarded.
After 7 days in culture, cells were trypsinised, counted and re-plated
at 36104 cells/cm2 in 24-well plates in control media. From this
time onwards media was changed 3 times per week.
Differentiation into mineral-producing osteoblasts was achieved
by culturing the cells in osteogenic media consisting of control
media supplemented with 50 mg/L ascorbic acid and 10 mM b-
glycerophosphate. Mineralisation of extracellular matrix was
visualised by von Kossa staining with 2% silver nitrate under
UV light for 30 minutes. The extent of mineralisation was
quantified using the Leica QWin imaging system (Leica Micro-
systems, Heerbrugg, Switzerland).
RNA Extraction and Quantitative Real-Time PCR
Following sacrifice by cervical dislocation, femurs and tibias
from 6–10 week old male mice were cleaned and snap frozen in
liquid nitrogen. Subsequently femurs and tibias from each leg were
homogenised separately in TRIzolH reagent using a polytron.
RNA extractions were carried out using TRIzolH reagent
according to the manufacturer’s instructions. RNA samples were
checked for quality and quantified using the Agilent 2100
Bioanalyser (Agilent Technologies) according to the manufactur-
er’s instructions. One microgram of total RNA was taken for
cDNA synthesis with oligo(dT)20 and random hexamers using the
SuperScript III First-Strand Synthesis System for reverse tran-
scription-PCR (Invitrogen). Quantitative real-time PCR was then
carried out using the TaqMan Universal PCR master mix
(Applied Biosystems), ABI Prism 7900 HT Sequence Detection
System and Software and inventoried kits containing primers and
probes from Applied Biosystems. To control for variability in
amplification due to differences in starting mRNA concentrations,
GAPDH was used as an internal standard. The relative expression
of target mRNA was computed from the target Ct values and the
GAPDH Ct value using the standard curve method (Sequence
Detection Systems Chemistry Guide, Applied Biosystems).
Statistical Analyses
Dual genotype comparisons were assessed using two-tailed
students T-test. Multiple genotype comparisons were assessed by
factorial ANOVA followed by Fisher’s or Contrasts post-hoc tests,
using StatView version 4.5 or Super-ANOVA (Abacus Concepts
Inc, CA, USA). For all statistical analyses, P,0.05 was accepted as
being statistically significant.
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